Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

Analyst recommends Novartis as a Buy for long-term investors, BioAge a Hold, following strategic partnership for age-related ...

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Anti-obesity medication: these are the surprising effects of taking Ozempic and Mounjaro - When Henry Conway hit his forties ...

The rise of GLP-1 drugs is sending the Diageo share price lower. But Stephen Wright thinks investors should try to avoid ...

Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.

(MENAFN- GlobeNewsWire - Nasdaq) First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk ... Patients refractory to non-steroidal anti-inflammatory ...